Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable

Journal of Psychopharmacology

Volumn 19, Issue 5 SUPPL., 2005, Pages 5-14

  Parellada, E ^a,i   Andrezina, R ^b   Milanova, V ^c   Glue, P ^d   Masiak, M ^e   Turner, M St John ^f   Medori, R ^g   Gaebel, W ^h  

^a HOSPITAL CLÍNIC   (Spain)

^b Department of Psychiatry   (Latvia)

^c UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

^d Distrikspyskiatrisk Team ^*  (Denmark)

^e MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^f Larkfield Centre   (United Kingdom)

^g Janssen Cilag EMEA Belgium   (Belgium)

^h HEINRICH HEINE UNIVERSITY   (Germany)

ⁱ UNIVERSITY OF BARCELONA   (Spain)

Author keywords

PANSS; Risperidone long acting injectable; Schizophrenia; Tolerability

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; LONG ACTING DRUG; OLANZAPINE; RISPERIDONE;

ADULT; ANXIETY; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DIABETES MELLITUS; DISEASE COURSE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DYSTONIA; FEMALE; GYNECOMASTIA; HEADACHE; HUMAN; HYPERPROLACTINEMIA; HYPERPYREXIA; INJECTION PAIN; INSOMNIA; LACTATION DISORDER; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PARKINSONISM; PATIENT COMPLIANCE; PATIENT SATISFACTION; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; RELAPSE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; QUALITY OF LIFE; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 25844468981     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/0269881105056513     Document Type: Article

References (35)

1. Berry S A, Clark A, Crumbley E, Zhu Y, Lasser R A (2004) Patients switched from olanzapine to long-acting risperidone in schizophrenia. 157th Annual Meeting of the American Psychiatric Association (APA), New York, N.Y., USA
2. Bradford D W, Perkins D O, Lieberman J A (2003) Pharmacological management of first-episode schizophrenia and related nonaffective psychoses. Drugs 63: 2265-2283
3. Bryden K E, Gardner D M, Kopala LC (2003) First episode psychosis: early intervention strategies with second-generation antipsychotic medications. Int J Clin Pract 57: 513-518
4. Clarke M, O'Callaghan E (2003) Is earlier better? At the beginning of schizophrenia: timing and opportunities for early intervention. Psychiatr Clin North Am 26: 65-83
5. Csernansky J G (2003) Treatment of schizophrenia: preventing the progression of disease. Psychiatr Clin North Am 26: 367-379
6. Emsley R A (1999) Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Schizophr Bull 25: 721-729
7. Eriksson L, Almqvist A, Mehnert A, Ingham M P, Eriksson B (2004) Treatment with long acting risperidone significantly reduces the need for institutional psychiatric care regardless of previous treatment. 45th Annual and 4th Mediterranean Meeting of the Scandinavian College of Neuro- Psychopharmacology, Juan-les-Pins, France, April 21-24. Nord J Psychiatry 58: Abstract 9
8. Fleischhacker W W, Eerdekens M, Karcher K, Remington G, Llorca P M, Chrzanowski W, Martin S, Gefvert O (2003) Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 64: 1250-1257
9. Gaebel W, Moller H J, Buchkremer G, Ohmann C, Riesbeck M, Wolwer W, Von Wilmsdorff M, Bottlender R, Klingberg S (2004) Pharmacological long-term treatment strategies in first episode schizophrenia-study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia. Eur Arch Psychiatry Clin Neurosci 254: 129-140
10. Gaebel W, Weinmann S, Sartorius N, Rutz W, McIntyre J (2005) Schizophrenia Practice Guidelines - An International Survey and Comparison. British Journal of Psychiatry: in press
11. Gutierrez Fraile M, Segarra Echevarria R, Gonzalez-Pinto Arrillaga A, Martinez Junquera G (2002) Risperidone in the early treatment of first-episode psychosis: a two-year follow-up study. Actas Esp Psiquiatr 30: 142-152
12. Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderung J, Dube K C, Ganev K, Giel R, an der Heiden W, Holmberg S K, Janca A, Lee P W, Leon C A, Malhotra S, Marsella A J, Nakane Y, Sartorius N, Shen Y, Skoda C, Thara R, Tsirkin S J, Varma V K, Walsh D, Wiersma D (2001) Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry 178: 506-517
13. Kane J M (2003) Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. J Clin Psychiatry 64 Suppl 16: 34-40
14. Kane J M, Aguglia E, Altamura A C, Ayuso Gutierrez J L, Brunello N, Fleischhacker W W, Gaebel W, Gerlach J, Guelfi J D, Kissling W, Lapierre Y D, Lindstrom E, Mendlewicz J, Racagni G, Carulla L S, Schooler N R (1998) Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 8: 55-66
15. Kane J M, Eerdekens M, Lindenmayer J P, Keith S J, Lesem M, Karcher K (2003a) Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 760: 1125-1132
16. Kane J M, Leucht S, Carpenter D, Docherty J P (2003b) Expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 64 Suppl 12:5-19
17. Lambert M, Conus P, Lambert T, McGorry P D (2003) Pharmacotherapy of first-episode psychosis. Expert Opin Pharmacother 4: 717-750
18. Lieberman J, Jody D, Geisler S, Alvir J, Loebel A, Szymanski S, Woerner M, Borenstein M (1993) Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 50: 369-376
19. Lieberman J A, Tollefson G, Tohen M, Green A I, Gur R E, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer R M (2003) Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, doubleblind trial of olanzapine versus haloperidol. Am J Psychiatry 160: 1396-1404
20. Lindenmayer J P, Eerdekens E, Berry S A, Eerdekens M (2004) Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 65: 1084-1089
21. Linszen D H, Dingemans P M, Lenior M E, Scholte W F, de Haan L, Goldstein M J (1998) Early detection and intervention in schizophrenia. Int Clin Psychopharmacol 13 Suppl 3: S31-34
22. Loebel A D, Lieberman J A, Alvir J M, Mayerhoff D I, Geisler S H, Szymanski S R (1992) Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 149: 1183-1188
23. McGlashan T H (1988) A selective review of recent North American long-term follow up studies of schizophrenia. Schizophr Bull 14: 515-542
24. McGlashan T H (1998) The profiles of clinical deterioration in schizophrenia. J Psychiatr Res 32: 133-141
25. McGlashan T H, Johannessen J O (1996) Early detection and intervention with schizophrenia: rationale. Schizophr Bull 22: 201-222
26. Marder S R, Davis J M, Chouinard G (1997) The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 58: 538-546
27. Medalia A, Lim R W (2004) Self-awareness of cognitive functioning in schizophrenia. Schizophr Res 71: 331-338
28. Moller H J, Llorca P M, Sacchetti E, Martin S D, Medori R, Parellada E (2005) Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 20: 121-130
29. Nasrallah H A, Duchesne I, Mehnert A, Janagap C, Eerdekens M (2004) Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. J Clin Psychiatry 65: 531-536
30. Ohlsen R I, O'Toole M S, Purvis R G, Walters J T, Taylor T M, Jones H M, Pilowsky L S (2004) Clinical effectiveness in first-episode patients. Eur Neuropsychopharmacol 14 Suppl 4: S445-451
31. Robinson D, Woerner M G, Alvir J M, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Lieberman J A (1999) Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56: 241-247
32. Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey P D, Kopala L, McGorry P D, Van Hove I, Eerdekens M, Swyzen W, De Smedt G (2005) Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 162: 947-953
33. van Bruggen J, Tijssen J, Dingemans P, Gersons B, Linszen D (2003) Symptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophrenia. Int Clin Psychopharmacol 18: 341-346
34. Waddington J, Quinn J (2000) From first to second generation antipsychotics. Birkhauser, Birkhauser
35. Wyatt R J, Henter I (2001) Rationale for the study of early intervention. Schizophr Res 51: 69-76